Citius Pharmaceuticals (CTXR) Free Cash Flow (2010 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Free Cash Flow came in at -$1.3 million in Q1 2026, up 71.36% YoY from -$758640.8 in Q1 2025, and up 90.01% on a QoQ basis from -$13.0 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Free Cash Flow (2010 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 17 years of Free Cash Flow data on file, last reported at -$1.3 million in Q1 2026.
- Quarterly Free Cash Flow rose 71.36% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$31.6 million (down 34.19% YoY) and the FY2025 annual result came in at -$26.6 million, up 53.09% from the prior year.
- Free Cash Flow advanced to -$1.3 million in Q1 2026, from -$13.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$1.3 million in Q1 2026 to a low of -$13.0 million in Q4 2025.
- A 5-year average of -$7.2 million and a median of -$6.8 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow soared 86.11% — and 2025, when it slumped 175.27%.
- Tracing CTXR's Free Cash Flow over 5 years: stood at -$4.8 million in 2022, then retreated by 27.17% to -$6.1 million in 2023, then gained by 22.97% to -$4.7 million in 2024, then tumbled by 175.27% to -$13.0 million in 2025, then jumped by 90.01% to -$1.3 million in 2026.
- The last three Free Cash Flow figures came in at -$1.3 million (Q1 2026), -$13.0 million (Q4 2025), and -$11.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Citius Pharmaceuticals | 15.71 Mn | 15.71 Mn | 1.00 Mn | -8.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.30 Mn |
| Mar 31, 2026 | -1.30 Mn |
| Dec 31, 2025 | -13.01 Mn |
| Dec 31, 2025 | -13.01 Mn |
| Sep 30, 2025 | -11.88 Mn |
| Sep 30, 2025 | -11.88 Mn |
| Jun 30, 2025 | -5.41 Mn |
| Jun 30, 2025 | -5.41 Mn |
| Mar 31, 2025 | -4.54 Mn |
| Mar 31, 2025 | -4.54 Mn |
| Dec 31, 2024 | -4.73 Mn |
| Dec 31, 2024 | -4.73 Mn |
| Sep 30, 2024 | -5.91 Mn |
| Sep 30, 2024 | -5.91 Mn |
| Jun 30, 2024 | -8.37 Mn |
| Jun 30, 2024 | -8.37 Mn |
| Mar 31, 2024 | -7.79 Mn |
| Mar 31, 2024 | -7.79 Mn |
| Dec 31, 2023 | -6.14 Mn |
| Dec 31, 2023 | -6.14 Mn |